Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Investment Conference.
A live webcast of the presentation will be available on the link provided below for approximately 30 days.
| Event | H.C. Wainwright Global Investment Conference |
| Date | May 24, 2022 |
| Time | 4:00 PM Eastern Time |
| Link | https://journey.ct.events/view/1ff8e74f-de55-4aad-bddf-9464a6c02784 |
About Nuvectis Pharma
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. The Company's pipeline includes NXP800, a clinical-stage HSF1-pathway inhibitor, and NXP900, a SRC/YES1 kinase inhibitor in IND-enabling pre-clinical testing.
For more information, please visit www.nuvectis.com.
Nuvectis Pharma Contact:
Ron Bentsur
Chairman, Chief Executive Officer and President
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Relations Contact:
Christopher M. Calabrese
LifeSci Advisors
Tel: 917-680-5608
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$6.35 |
| Daily Change: | 0.29 4.79 |
| Daily Volume: | 71,948 |
| Market Cap: | US$162.600M |
November 04, 2025 September 25, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
